Clinical trials: Neoplasm, Bronchial
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Provide expanded access of cemiplimab in patients with solid tumors
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06132191
- Testing
- Cemiplimab
- Sponsor
- Regeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system.
- Trial name
- NCT00132379
- Testing
- ABR-217620, docetaxel
- Where
- 4 sites in United States, Denmark and 1 more
- Volunteers
- 13 people
- Sponsor
- Active Biotech AB
Non-Small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00034346
- Testing
- ABX-EGF, paclitaxel, carboplatin
- Volunteers
- 194 people
- Sponsor
- Amgen
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Non-small Cell Lung Carcinoma
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung…
- Trial name
- NCT02039674
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Traumatic Brain Injury
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury…
- Trial name
- NCT04063215
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences LLC
Lung Cancer, Non-Small Cell
A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors
This is an open-label, two-arm, Phase I, dose escalation study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) of pazopanib in combination with erlotinib (Arm A) or pazopanib in…
- Trial name
- NCT00619424
- Testing
- pazopanib, erlotinib, pemetrexed
- Where
- 4 sites in United States, Italy
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Lung cancer has the highest incidence rate in China and is also a very common cancer in the world. BPI-7711 is a new drug developed for patients with non-small cell lung cancer.
- Trial name
- NCT03386955
- Testing
- BPI-7711 Capsule
- Where
- 4 sites in China
- Volunteers
- 215 people
- Sponsor
- Beta Pharma Shanghai
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.
Non-small Cell Lung Cancer
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
The purpose of this study is to assess the short and long-term outcomes after CyberKnife stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who are medically inoperable.
- Trial name
- NCT00643318
- Testing
- CyberKnife Stereotactic Radiosurgery
- Where
- 23 sites in United States, China
- Volunteers
- 40 people
- Sponsor
- Accuray Incorporated
Carcinoma, Non-Small-Cell Lung
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
- Trial name
- NCT01209650
- Testing
- BIBW 2992
- Where
- Australia
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
To investigate efficacy and safety of the combination with pemetrexed plus carboplatin, followed by pemetrexed in patients with advanced nonsquamous Non Small Cell Lung Cancer (NSCLC) who receive at least one dose of the…
- Trial name
- NCT01020786
- Testing
- Pemetrexed, Carboplatin
- Where
- 16 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker…
- Trial name
- NCT05257551
- Testing
- Observation
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Tempus AI
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Non-Small Cell Lung Cancer, Advanced Solid Tumours
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
A Phase I, open-label, multicentre, dose-escalation study to investigate the safety, pharmacokinetics and maximum tolerated dose (MTD) of AZD4785 in patients with advanced solid tumours where KRAS may be an important driver of…
- Trial name
- NCT03101839
- Testing
- AZD4785
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Advanced Non-small Cell Lung Cancer
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
The main object of this trial is to offer treatment of recombinant endostatin ( Sulijia) combined with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer, expecting to…
- Trial name
- NCT03117335
- Testing
- Sulijia
- Where
- 37 sites in China
- Volunteers
- 560 people
- Sponsor
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, demcizumab (OMP-21M18), when given in combination with carboplatin and pemetrexed, a standard drug treatment regimen for non-squamous…
- Trial name
- NCT01189968
- Testing
- Demcizumab
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
- Trial name
- NCT02906150
- Testing
- Thymalfasin (Thymosin alpha 1, Ta1), SoC (chemotherapy and platinum agent)
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- SciClone Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer.
- Trial name
- NCT00073151
- Testing
- ABT-751
- Where
- 17 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this clinical trial is to compare Utidelone with Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously failed platinum-containing chemotherapy regimens.
- Trial name
- NCT05673590
- Testing
- Utidelone Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.